# US 2021/0198294 A1 · Novel Lipids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198294 A1
- Document ID: US20210198294A1
- Status: Published application
- Kind: A1
- Application number: 17/191,214
- Filed: 2021-03-03
- Published: 2021-07-01
- Earliest claimed: 2018-06-26
- Assignees: Signpath Pharma, Inc.
- Applicants: Signpath Pharma, Inc.
- Inventors: James McChesney; Annie Bouchard; Saravanan Kappusamy; John Kallikat Augustine; Daniel Emil Levy
- Web page: https://patentgrep.com/patent/US20210198294A1

## CPC

- C07F 9/09: Esters of phosphoric acids
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07F 9/091: {with hydroxyalkyl compounds with further substituents on alkyl}
- C07F 9/65515: {the oxygen atom being part of a five-membered ring}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention includes compound having the following structural formula:

## Claims

### Claim 1

A compound of Formula I,
wherein,
R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R3 is
R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R8 is H or a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
X is a direct linkage, CH2, O or NH;
Y is a direct linkage, CH2, O or NH; and,
Each stereogenic center is independently R, S or racemic.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R4 is H, Li, Na, K, Mg, Ca, Zn, Cs, ammonium or tetraalkylammonium.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is selected from at least one of:

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is a single entity, a solvate, a hydrate, a crystal, an amorphous solid, a liquid or an oil.

### Claim 5

A method of preparing a compound of Formula I
wherein,
R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R3 is
R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R8 is H or a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
X is a direct linkage, CH2, O or NH;
Y is a direct linkage, CH2, O or NH; and,
Each stereogenic center is independently R, S or racemic;
Comprising the steps of:
(1) Converting the hydroxyl groups of a compound of Formula II to esters, carbonates, carbamates, or collectively to an acetal or a ketal
wherein, all substitutions are defined as above; and
(2) Converting a phosphorus-bound OH group to O—R4, wherein R4 is not H; or
Comprising the steps of:
(1) Linking a compound of Formula III with a compound of Formula IV or with a compound of Formula V through creation of a phosphate diester bridge
wherein, all substitutions are defined as above; and
(2) Converting a phosphorus-bound OH group to O—R4, wherein R4 is not H.

### Claim 6 (depends on 5)

The method of claim 5, wherein the method comprises the steps of
(1) Converting the hydroxyl groups of a compound of Formula II to esters, carbonates, carbamates, or collectively to an acetal or a ketal
wherein, all substitutions are defined as above; and
(2) Converting a phosphorus-bound OH group to O—R4, wherein R4 is not H.

### Claim 7 (depends on 5)

The method of claim 5, wherein the method comprises the steps of
(1) Linking a compound of Formula III with a compound of Formula IV or with a compound of Formula V through creation of a phosphate diester bridge
wherein, all substitutions are defined as above; and
(2) Converting a phosphorus-bound OH group to O—R4, wherein R4 is not H.

### Claim 8 (depends on 5)

The method of claim 5, wherein R4 is H, Li, Na, K, Mg, Ca, Zn, Cs, ammonium or tetraalkylammonium.

### Claim 9 (depends on 5)

The method of claim 5, wherein the compound is selected from at least one of:

### Claim 10 (depends on 5)

The method of claim 5, wherein the method produces compounds that individually exist as a single entity, a solvate, a hydrate, a crystal, an amorphous solid, a liquid, or an oil.

### Claim 11

A pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable diluent or carrier
wherein,
R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R3 is
R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R8 is H or a C0-C2 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
X is a direct linkage, CH2, O or NH;
Y is a direct linkage, CH2, O or NH; and,
each stereogenic center is independently R, S or racemic.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein R4 of the compound of Formula I is H, Li, Na, K, Mg, Ca, Zn, Cs, ammonium or tetraalkylammonium.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the compound of Formula I is selected from one or more of:

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the compound of Formula I exists as a single entity, a solvate, a hydrate, a crystal, an amorphous solid, a liquid or an oil.

### Claim 15 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition further comprises one or more agents that induce a cardiopathy as a side effect.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein one or more agents that induces a cardiopathy as a side effect is selected from at least one of: Albuterol, Alfuzosin, Amantadine, Amiodarone, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, Anagrelide, Apomorphine, Arformoterol, Aripiprazole, Arsenic trioxide, Astemizole, Atazanavir, Atomoxetine, Azithromycin, Bedaquiline, Bepridil, Bortezomib, Bosutinib, Chloral hydrate, Chloroquine, Chlorpromazine, Ciprofloxacin, Cisapride, Citalopram, Clarithromycin, Clomipramine, Clozapine, Cocaine, Curcumin, Crizotinib, Dabrafenib, Dasatinib, Desipramine, Dexmedetomidine, Dexmethylphenidate, Dextroamphetamine, Amphetamine, Dihydroartemisinin and Piperaquine, Diphenhydramine, Disopyramide, Dobutamine, Dofetilide, Dolasetron, Domperidone, Dopamine, Doxepin, Dronedarone, Droperidol, Ephedrine, Epinephrine, Adrenaline, Eribulin, Erythromycin, Escitalopram, Famotidine, Felbamate, Fenfluramine, Fingolimod, Flecainide, Fluconazole, Fluoxetine, Formoterol, Foscarnet, Fosphenytoin, Furosemide, Frusemide, Galantamine, Gatifloxacin, Gemifloxacin, Granisetron, Halofantrine, Haloperidol, Hydrochlorothiazide, Ibutilide, Iloperidone, Imipramine, Melipramine, Indapamide, Isoproterenol, Isradipine, Itraconazole, Ivabradine, Ketoconazole, Lapatinib, Levalbuterol, Levofloxacin, Levomethadyl, Lisdexamfetamine, Lithium, Mesoridazine, Metaproterenol, Methadone, Methamphetamine, Methylphenidate, Midodrine, Mifepristone, Mirabegron, Mirtazapine, Moexipril/HCTZ, Moxifloxacin, Nelfinavir, Nicardipine, Nilotinib, Norepinephrine, Norfloxacin, Nortriptyline, Ofloxacin, Olanzapine, Ondansetron, Oxytocin, Paliperidone, Paroxetine, Pasireotide, Pazopanib, Pentamidine, Perflutren lipid microspheres, Phentermine, Phenylephrine, Phenylpropanolamine, Pimozide, Posaconazole, Probucol, Procainamide, Promethazine, Protriptyline, Pseudoephedrine, Quetiapine, Quinidine, Quinine sulfate, Ranolazine, Rilpivirine, Risperidone, Ritodrine, Ritonavir, Roxithromycin, Salbutamol, Salmeterol, Saquinavir, Sertindole, Sertraline, Sevoflurane, Sibutramine, Solifenacin, Sorafenib, Sotalol, Sparfloxacin, Sulpiride, Sunitinib, Tacrolimus, Tamoxifen, Telaprevir, Telavancin, Telithromycin, Terbutaline, Terfenadine, Tetrabenazine, Thioridazine, Tizanidine, Tolterodine, Toremifene, Trazodone, Trimethoprim-Sulfa, Trimipramine, Vandetanib, Vardenafil, Vemurafenib, Venlafaxine, Voriconazole, Vorinostat, or Ziprasidone.

### Claim 17 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition further comprises one or more excipients, binders, anti-adherents, coatings, disintegrants, fillers, flavors, dyes, colors, glidants, lubricants, preservatives, sorbents, sweeteners, derivatives thereof, or combinations thereof.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the binder is selected from the group consisting of hydroxypropylmethylcellulose, ethyl cellulose, povidone, acrylic and methacrylic acid co-polymers, pharmaceutical glaze, gums, and milk derivatives.

### Claim 19 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition comprises a compound of Formula I in an amount per unit dose of between about 1 mg and about 1 gram per unit dose.

### Claim 20 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is a formulation for oral, sublingual, transdermal, suppository, intrathecal, enteral, parenteral, intravenous, intraperitoneal, cutaneous, subcutaneous, topical, pulmonary, rectal, vaginal, or intramuscular administration.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the formulation for oral administration is a tablet, capsule, caplet, pill, powder, troche, lozenge, slurry, liquid solution, suspension, emulsion, elixir or oral thin film (OTF).

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the formulation is a solid form, a solution, a suspension, or a soft gel form.

### Claim 23

A method of reducing or eliminating one or more of a cardiac channelopathy, cardiac muscle damage, or a condition resulting from the irregularity or alteration in the cardiac pattern, in a human or animal subject, comprising the step of administering to the human or animal subject one or more of a compound of Formula I
wherein,
R1 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R2 is a C1-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R3 is
R4 is H or a pharmaceutically acceptable cation, wherein incorporation of said pharmaceutically acceptable cation results in a salt;
R5 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R6 is a C1-C10 branched or unbranched hydrocarbon optionally substituted with one or more groups selected from OH, OAc, OMe, NH2, NHAc, NHMe, N(Me)2, SH, CN, COOH, CONH2, Cl, Br and I;
R7 is a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
R8 is H or a C0-C20 branched or unbranched hydrocarbon possessing 0-10 double bonds, 0-10 triple bonds or a combination of 0-10 double and triple bonds;
X is a direct linkage, CH2, O or NH;
Y is a direct linkage, CH2, O or NH; and
wherein each stereogenic center is independently R, S or racemic.

### Claim 24 (depends on 23)

The method of claim 23, wherein the R4 of the compound of Formula I is H, Li, Na, K, Mg, Ca, Zn, Cs, ammonium or tetraalkylammonium.

### Claim 25 (depends on 23)

The method of claim 23, wherein the compound of Formula I exists as a single entity, a solvate, a hydrate, a crystal, an amorphous solid, a liquid or an oil.

### Claim 26 (depends on 23)

The method of claim 23, wherein the compound of Formula I reduces or eliminates one or more of a cardiac channelopathy or a condition resulting from the irregularity or alteration in the cardiac pattern caused by the active agent used to treat a disease.

### Claim 27 (depends on 23)

The method of claim 23, wherein the compound of Formula I is administered in an amount per unit dose of between about 1 mg and about 1 gram.

### Claim 28 (depends on 23)

The method of claim 23, wherein the compound of Formula I is formulated for oral, sublingual, transdermal, suppository, intrathecal, enteral, parenteral, intravenous, intraperitoneal, cutaneous, subcutaneous, topical, pulmonary, rectal, vaginal, or intramuscular administration.

### Claim 29 (depends on 28)

The method of claim 28, wherein the compound of Formula I is formulated for oral administration as a tablet, capsule, caplet, pill, powder, troche, lozenge, slurry, liquid solution, suspension, emulsion, elixir or oral thin film (OTF).

### Claim 30 (depends on 23)

The method of claim 23, wherein the compound of Formula I is formulated as a solid form, a solution, a suspension, or a soft gel form.

### Claim 31 (depends on 30)

The method of claim 30, wherein the solid form further comprises one or more excipients, binders, anti-adherents, coatings, disintegrants, fillers, flavors, dyes, colors, glidants, lubricants, preservatives, sorbents, sweeteners, derivatives thereof, or combinations thereof.

### Claim 32 (depends on 31)

The method of claim 31, wherein the compound of Formula I is co-administered with one or more agents that induce a cardiopathy as a side effect.

### Claim 33 (depends on 32)

The method of claim 32, wherein the one or more active agent that induce a cardiopathy as a side effect are selected from at least one of: Albuterol, Alfuzosin, Amantadine, Amiodarone, Amisulpride, Amitriptyline, Amoxapine, Amphetamine, Anagrelide, Apomorphine, Arformoterol, Aripiprazole, Arsenic trioxide, Astemizole, Atazanavir, Atomoxetine, Azithromycin, Bedaquiline, Bepridil, Bortezomib, Bosutinib, Chloral hydrate, Chloroquine, Chlorpromazine, Ciprofloxacin, Cisapride, Citalopram, Clarithromycin, Clomipramine, Clozapine, Cocaine, Curcumin, Crizotinib, Dabrafenib, Dasatinib, Desipramine, Dexmedetomidine, Dexmethylphenidate, Dextroamphetamine, Amphetamine, Dihydroartemisinin and Piperaquine, Diphenhydramine, Disopyramide, Dobutamine, Dofetilide, Dolasetron, Domperidone, Dopamine, Doxepin, Dronedarone, Droperidol, Ephedrine, Epinephrine, Adrenaline, Eribulin, Erythromycin, Escitalopram, Famotidine, Felbamate, Fenfluramine, Fingolimod, Flecainide, Fluconazole, Fluoxetine, Formoterol, Foscarnet, Fosphenytoin, Furosemide, Frusemide, Galantamine, Gatifloxacin, Gemifloxacin, Granisetron, Halofantrine, Haloperidol, Hydrochlorothiazide, Ibutilide, Iloperidone, Imipramine, Melipramine, Indapamide, Isoproterenol, Isradipine, Itraconazole, Ivabradine, Ketoconazole, Lapatinib, Levalbuterol, Levofloxacin, Levomethadyl, Lisdexamfetamine, Lithium, Mesoridazine, Metaproterenol, Methadone, Methamphetamine, Methylphenidate, Midodrine, Mifepristone, Mirabegron, Mirtazapine, Moexipril/HCTZ, Moxifloxacin, Nelfinavir, Nicardipine, Nilotinib, Norepinephrine, Norfloxacin, Nortriptyline, Ofloxacin, Olanzapine, Ondansetron, Oxytocin, Paliperidone, Paroxetine, Pasireotide, Pazopanib, Pentamidine, Perflutren, Phentermine, Phenylephrine, Phenylpropanolamine, Pimozide, Posaconazole, Probucol, Procainamide, Promethazine, Protriptyline, Pseudoephedrine, Quetiapine, Quinidine, Quinine sulfate, Ranolazine, Rilpivirine, Risperidone, Ritodrine, Ritonavir, Roxithromycin, Salbutamol, Salmeterol, Saquinavir, Sertindole, Sertraline, Sevoflurane, Sibutramine, Solifenacin, Sorafenib, Sotalol, Sparfloxacin, Sulpiride, Sunitinib, Tacrolimus, Tamoxifen, Telaprevir, Telavancin, Telithromycin, Terbutaline, Terfenadine, Tetrabenazine, Thioridazine, Tizanidine, Tolterodine, Toremifene, Trazodone, Trimethoprim-Sulfa, Trimipramine, Vandetanib, Vardenafil, Vemurafenib, Venlafaxine, Voriconazole, Vorinostat, or Ziprasidone.

### Claim 34 (depends on 23)

The method of claim 23, wherein the compound of Formula I reduces or eliminates cardiopathies, such as QT prolongation, cardiac muscle damage, or AV block, that are drug-induced or caused by a disease or condition.
